ImageneBio, Inc. (IMA) stock

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$3.47+0.02 (+0.58%)

Close on Nov 13, 2026Market cap $39.39MP/E –Yield –

ImageneBio price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

ImageneBio's price to sales ratio was 36.7× on Apr 30, 2026, against 83.5× a year earlier. Over the last 4 years it ranged from 30.4× to 498.4×, with a median of 96.1×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	36.7×	−96.7
2025	Dec 31, 2025	133.4×	+49.9
2024	Apr 30, 2024	83.5×	+8.7
2023	Dec 29, 2023	74.7×	+36.6
2022	Dec 30, 2022	38.1×	−460.3
2021	Dec 31, 2021	498.4×	–

Where these numbers come from

Parsed from the XBRL in ImageneBio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Jul 28, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMA.

Compare: IMA vs CMPX · IMA vs ARTV · IMA vs SABS · IMA vs PALI · IMA vs INBX

Company	Revenue	Growth
IMA	$800.00K	-77.1%
PALI	$500.00K	–
CMPX	–	–
ARTV	–	–
SABS	–	–
INBX	–	–

Company

Next earnings (est.): Mar 9, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 15
Held by institutions: 54.9%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1835579

Advertisement
300 × 250

See a number that looks wrong?

ImageneBio price to sales ratio

Price to Sales Ratio at the end of each year

More ImageneBio figures